melanoma
Conditions
Interventions
Anti-cancer drug (combination with carboplatin and paclitaxel)
Sponsors
Division of Skin Oncology, Comprehensive cancer center, Saitama medical university International medical center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histopathologically proven melanoma patients. 2. Patients who have unresectable metastasis. 3. At least 4 weeks after dacarbadine-based chemotherapy. 4. Patients who have a life expectancy of more than 3 months. 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 6. Patients whose age is more than 18 years old, regardless of sex. 7. Patients who have given informed consent 8. Patients without severe disorders -Neutrophilic leukocyte >1,500/mm3,PLT>100,000/mm3 -liver function (AST< 1.5 folds of upper normal limit) -renal function (Cre<1.5 mg/dl)
Exclusion criteria
Exclusion criteria: 1. Patients who have brain metastases which are not controlled by surgery or radiotherapy 2. Patients without myelosuppresion-Neutrophilic leukocyte<1,500/mm3, PLT<100,000/mm3 3. Patients with severe disorders in heart (NYHA Grade 2 or more), lung, liver, kidney or brain. 4. Patients who are pregnant or nursing 5. Patients who are judged inappropriate to be enrolled in this study by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of combination therapy with carboplatin and paclitaxel in patients with metastatic melanoma | — |
Countries
Japan
Contacts
Public ContactYukiko Teramoto, M.D.
Saitama medical university International medical center Division of Skin Oncology
Outcome results
None listed